RedHill Biopharma Ltd. (NASDAQ:RDHL)

RedHill Biopharma Ltd. RDHL

Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - IL

Watchlist

$ 7.29

6.11 %

$ 9.29 M

Market Cap

-0.02

P/E

1. INTRINSIC VALUE

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study.[ Read More ]

The intrinsic value of one RDHL stock under the base case scenario is HIDDEN Compared to the current market price of 7.29 USD, RedHill Biopharma Ltd. is HIDDEN

RDHL Intrinsic Value
HIDDEN

SHOW

2. FUNDAMENTAL ANALYSIS

Price Chart RDHL

FINANCIALS

Annual
Quarterly

6.51 M REVENUE

Growth Rates

1Year -89.46%

3Years -53.40%

5Years -4.87%

7Years 81.34%

10Years 87.70%

12.6 M OPERATING INCOME

Growth Rates

1Year 129.48%

3Years 30.03%

5Years 18.34%

7Years 13.41%

10Years 12.24%

23.9 M NET INCOME

Growth Rates

1Year 133.37%

3Years 32.27%

5Years 21.21%

7Years 15.93%

10Years 15.57%

-35.8 M OPERATING CASH FLOW

Growth Rates

1Year -22.73%

3Years 9.66%

5Years -0.78%

7Years -3.45%

10Years -15.56%

3.99 K INVESTING CASH FLOW

Growth Rates

1Year -99.95%

3Years 25.99%

5Years -76.31%

7Years -71.23%

10Years -43.14%

21.4 M FINANCING CASH FLOW

Growth Rates

1Year 86.71%

3Years -36.72%

5Years -12.53%

7Years -7.18%

10Years 25.09%

1.8 M REVENUE

Growth Rates

1Year -89.46%

3Years -53.40%

5Years -4.87%

7Years 81.34%

10Years 87.70%

-4.41 M OPERATING INCOME

Growth Rates

1Year 129.48%

3Years 30.03%

5Years 18.34%

7Years 13.41%

10Years 12.24%

761 K NET INCOME

Growth Rates

1Year 133.37%

3Years 32.27%

5Years 21.21%

7Years 15.93%

10Years 15.57%

-10.6 M OPERATING CASH FLOW

Growth Rates

1Year -22.73%

3Years 9.66%

5Years -0.78%

7Years -3.45%

10Years -15.56%

-7 K INVESTING CASH FLOW

Growth Rates

1Year -99.95%

3Years 25.99%

5Years -76.31%

7Years -71.23%

10Years -43.14%

3 K FINANCING CASH FLOW

Growth Rates

1Year 86.71%

3Years -36.72%

5Years -12.53%

7Years -7.18%

10Years 25.09%

Balance Sheet Decomposition RedHill Biopharma Ltd.

23 M ASSETS
21 M LIABILITIES

Current Assets	16.1 M
Cash & Short-Term Investments	6.36 M
Receivables	3.29 M
Other Current Assets	6.5 M
Non-Current Assets	6.91 M
Long-Term Investments	147 K
PP&E	1.18 M
Other Non-Current Assets	5.58 M

Current Liabilities	19.2 M
Accounts Payable	3.28 M
Short-Term Debt	718 K
Other Current Liabilities	15.2 M
Non-Current Liabilities	1.74 M
Long-Term Debt	455 K
Other Non-Current Liabilities	1.28 M

EFFICIENCY

Earnings Waterfall RedHill Biopharma Ltd.

Revenue	6.51 M
Cost Of Revenue	3.46 M
Gross Profit	3.05 M
Operating Expenses	-9.56 M
Operating Income	12.6 M
Other Expenses	-11.3 M
Net Income	23.9 M

RATIOS

46.89% GROSS MARGIN

Averages

1Year 46.89%

3Years 45.11%

5Years 48.42%

7Years 50.73%

10Years -76300.05%

193.95% OPERATING MARGIN

Averages

1Year 193.95%

3Years 10.00%

5Years -151.13%

7Years -360.45%

10Years -76631.55%

367.19% NET MARGIN

Averages

1Year 367.19%

3Years 46.01%

5Years -138.78%

7Years -327.83%

10Years -73452.68%

1155.91% ROE

Averages

1Year 1155.91%

3Years -3.23%

5Years -144.90%

7Years -128.77%

10Years -102.62%

103.77% ROA

Averages

1Year 103.77%

3Years 1.13%

5Years -20.98%

7Years -35.22%

10Years -35.48%

610.53% ROIC

Averages

1Year 610.53%

3Years 151.65%

5Years 60.51%

7Years 13.29%

10Years -3.94%

FREE CASH FLOW ANALYSIS

Free Cash Flow Analysis RedHill Biopharma Ltd.

Net Income	23.9 M
Depreciation & Amortization	1.99 M
Capital Expenditures	-11 K
Stock-Based Compensation	1.65 M
Change in Working Capital	-15.6 M
Others	-98.2 M
Free Cash Flow	-35.8 M

3. WALL STREET ANALYSTS ESTIMATES

Wall Street Analysts Price Targets RedHill Biopharma Ltd.

RDHL has no price targets from Wall Street.

4. DIVIDEND ANALYSIS

0.00% DIVIDEND YIELD

0 USD DIVIDEND PER SHARE

5. COMPETITION

Organogenesis Holdings Inc., a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States.

-2.27 USD

ORGO

Overvalued 158.70%

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally.

-6.25 USD

LFCR

Overvalued 197.68%

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment.

57.1 USD

COLL

Undervalued 93.04%

Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally.

-3.09 USD

AQST

Overvalued 169.57%

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases.

-0.151 USD

EVOK

Overvalued 103.30%

Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED).

0 USD

PTPI

Overvalued 100.00%

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United States and internationally.

10.5 USD

CPIX

Undervalued 821.57%

PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel.

6.07 USD

PRFX

Undervalued 1044.26%

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine piece tablets (TCMP) in China.

11.6 USD

SXTC

Undervalued 2902.92%

Alpha Teknova, Inc. provides critical reagents for life sciences market in the United States and internationally. Its reagents enable the discovery, development, and production of biopharmaceutical products, such as drug therapies, novel vaccines, and molecular diagnostics.

0 USD

TKNO

Overvalued 100.00%

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease.

0 USD

CYTH

Overvalued 100.00%

6. Ownership

Insider Ownership RedHill Biopharma Ltd.

Summary
Transactions

Sold

0-3 MONTHS

0 USD 0

3-6 MONTHS

0 USD 0

6-9 MONTHS

0 USD 0

9-12 MONTHS

0 USD 0

Bought

0 USD 0

0-3 MONTHS

0 USD 0

3-6 MONTHS

0 USD 0

6-9 MONTHS

0 USD 0

9-12 MONTHS

Date	Value	Insider	Amount	Avg Price

7. News

RedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRND RedHill has been selected to provide a presentation to further elaborate on opaganib's potential to U.S. government representatives at the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense's (JPEO-CBRND) "Host Directed Therapeutics Industry Day" -- Based on reviews, feedback, and discussion, the judges selected for presentation those therapeutics that demonstrated capability in the prophylaxis, post-exposure prophylaxis, and the treatment of exposure to viruses, bacteria and toxins. The meeting is scheduled to take place October 29-30, 2024, at the United States Patent and Trademark Office in Alexandria, VA -- The JPEO-CBRND manages U.S. government investments in chemical, biological, radiological, and nuclear (CBRN) defense equipment and medical countermeasures (MCMs). prnewswire.com - 2 weeks ago

RedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation Injury The collaboration outlines plans for multiple in vivo studies, designed to test opaganib as a potential medical countermeasure to treat phosgene inhalation injury. The collaboration aims to determine whether opaganib can advance into further definitive U.S. government-sponsored development under the FDA's Animal Rule pathway to approval Used as a chemical weapon during World War I, phosgene, a toxic, colorless chemical, is today widely used in industrial processes for the manufacture of plastics and pesticides. prnewswire.com - 3 weeks ago

RedHill Biopharma Secures U.S. Government Funding through BARDA to Advance Opaganib for Ebola Treatment The U.S. government's Biomedical Advanced Research and Development Authority (BARDA) selected opaganib for joint development & funding as a medical countermeasure (MCM) to treat Ebola virus disease (EBOV) -- The funding advances opaganib's positive development progress to date on the expected FDA Animal Rule pathway toward potential approval as an MCM for EBOV -- Recent U.S. Army-funded studies showed that opaganib delivered a statistically significant increase in survival in an in vivo EBOV model. The BARDA research and development contract provides initial funding for the collaboration, in pursuit of advancing opaganib to mitigate infection and contain EBOV outbreaks -- This year marks the 10th anniversary of the West Africa Ebola epidemic in which 11,000 people died, and there is still an urgent need for effective and useable therapies, with EBOV proving fatal in around half of all cases according to the World Health Organization (WHO) 1 -- Opaganib, a novel potentially broad-acting drug, has shown mutation-resistant antiviral and anti-inflammatory activity, likely to directly impact vascular health - one of the main targets for EBOV dysfunction. prnewswire.com - 1 month ago

RedHill and Medi-Cal Deal Maintains Talicia® Reimbursement Without Prior Authorization for 15 Million Californians Medi-Cal, California's Medicaid healthcare program, and RedHill have renewed their contract to maintain Talicia's first-line position on the Medi-Cal Fee-For-Service (FFS) Contract Drug List (CDL) with no prior authorization and a $0 copay – a major benefit for approximately fifteen million Californian Medi-Cal patients -- The renewed terms reflect both parties' ongoing commitment to improving patient access and outcomes, reinforcing Talicia's role as an essential treatment option, and follow the new American College of Gastroenterology (ACG) Clinical Guideline 1 for H. pylori infection, listing Talicia as an empirically prescribed first-line option -- Talicia's convenient all-in-one three-times daily (TID) formulation offers a simplified patient experience, supporting high rates of H. prnewswire.com - 1 month ago

RedHill Announces New U.S. Coronavirus Patent for Opaganib, Valid Through 2041 New U.S. patent issued covering the identification of a novel biomarker of coronavirus pneumonia (≤60% fraction of inspired oxygen (FiO2)) prognostic for potential opaganib efficacy in treating COVID-19, valid through 204 Published post-hoc data from opaganib's Phase2/3 study showed that patients with ≤60% FiO2 levels had better outcomes after 14 days' opaganib treatment (n=117) compared to placebo (n=134), including: increased number of patients no longer requiring supplemental oxygen by day 14 of opaganib treatment (76.9% vs. 63.4%; p-value =0.033), a 62.6% reduction in intubation/mechanical ventilation (6.84% vs. prnewswire.com - 1 month ago

RedHill's Talicia® Listed as First-Line Choice for H. pylori in New American College of Gastroenterology Guidelines First new American College of Gastroenterology (ACG) Clinical Guideline [1] for H. pylori infection since Talicia's approval lists Talicia as an empirically prescribed first-line option Talicia's convenient all-in-one three times daily (TID) formulation offers a simplified patient experience, supporting high rates of eradication without needing prior resistance testing Talicia is the leading branded first-line therapy prescribed by U.S. gastroenterologists [2] for H. prnewswire.com - 2 months ago

RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement TEL AVIV, Israel and RALEIGH, N.C. , Sept. 5, 2024 /PRNewswire/ -- RedHill Biopharma Ltd. prnewswire.com - 2 months ago

New Peer-Reviewed Publication of Opaganib Phase 2/3 Data Shows 62% Reduction in COVID-19 Mortality Data, from a post hoc analysis of the randomized, placebo-controlled, double-blind phase 2/3 study of oral opaganib in COVID-19 pneumonia, showing a 62% reduction in mortality and a 21% improvement in time to room air (no longer needing supplemental oxygen), has been newly published in the peer-reviewed journal, Microorganisms The analysis, from a large sub-group of 251 hospitalized, moderately severe COVID-19 patients requiring a fraction of inspired oxygen (FiO2) up to and including 60%, also indicates that FiO2 of greater than 60% may represent a threshold level for disease severity, and may potentially be a patient selection biomarker, an important finding for future therapeutic strategies and studies With 30,000 Americans dead due to COVID-19 so far this year according to the World health Organization[1], new, effective and safe therapies are still very much needed With multiple U.S. government collaborations ongoing, opaganib is a novel, host-directed, potentially broad acting, orally administered small molecule drug with demonstrated safety & efficacy profiles in oncology indications, viral infection, nuclear/radioprotection and other inflammatory diseases TEL AVIV, Israel and RALEIGH, N.C., Sept. 3, 2024 /PRNewswire/ -- RedHill Biopharma Ltd. prnewswire.com - 2 months ago

RedHill Biopharma Announces First Half 2024 Business Highlights A transformed RedHill: Numerous potential catalysts Strengthened cash balance and control over our destiny following the Termination Agreement with Movantik Acquisition Co. and others : Executing on our plan to ensure a value-driven focus, operational efficiency and financial streamlining with a low cost-base U.S. government collaborations : Developing a promising, advancing and largely financially de-risked pipeline via U.S. government and other collaborations Addressing substantial and underserved indications : In oncology viral pandemic preparedness, nuclear/radioprotection, and obesity/diabetes Building value : In the lab and in the clinic through new studies, generating new intellectual property and publications and forging the right partnerships for our assets Streamlined U.S. commercial organization : Cost reduction measures resulted in a much smaller, more efficient and cost-effective organization while still maintaining a leadership position with Talicia ® R&D and Commercial Highlights : Opaganib: - U.S. Army program for Ebola (believed to be the first host-directed molecule to show activity in vivo in Ebola virus disease)- Orphan drug designation granted by FDA for neuroblastoma - Discussions ongoing for a potential externally-funded, mid-stage clinical study in an additional underserved oncology indication - U.S. government-funded programs ongoing with the NIH / BARDA-funded nuclear and chemical medical countermeasure programs for Acute Radiation Syndrome (ARS) and Sulfur Mustard exposure - Positive in vivo study results support potential of opaganib therapy in diabetes / obesity RHB-107: - COVID-19: Enrollment ongoing in the U.S Department of Defense-supported 300-patient Phase 2 ACESO PROTECT platform trial for early COVID-19 outpatient treatment; enrollment estimated to be completed in the first half of 2025 - U.S. Army-funded Ebola development program ongoing; RHB-107 also demonstrated robust synergistic effect in vitro when combined with remdesivir RHB-104 : Newly published positive Phase 3 data demonstrated 64% increased efficacy with RHB-104 in Crohn's disease Talicia: The leading prescribed branded H. pylori therapy in the U.S., maintaining leadership position with a streamlined commercial team: - Expected upcoming new H. prnewswire.com - 2 months ago

RedHill's Opaganib Granted Orphan Drug Designation by the FDA for Childhood Cancer, Neuroblastoma Neuroblastoma is rare but is the most common infancy malignancy with a median age of diagnosis of 17 months. In the U.S., it accounts for up to around 10% of all childhood cancer cases and 15% of pediatric cancer-related deaths [1], [2] Orphan Drug designation provides for seven-years' marketing exclusivity should opaganib be approved in neuroblastoma and may confer additional benefits such as accelerated development and review times, potential grant funding and possible tax credits The neuroblastoma market is expected to reach almost $1.5 billion before mid-2030s [3] This is the second orphan drug designation by the FDA for opaganib in oncology, after cholangiocarcinoma (bile duct cancer, CCA) With multiple U.S. government collaborations ongoing, opaganib is a novel, host-directed, potentially broad acting, orally administered small molecule drug with demonstrated safety & efficacy profiles TEL AVIV, Israel and RALEIGH, N.C. prnewswire.com - 2 months ago

Talicia® Launched in the United Arab Emirates RedHill's Talicia, the first approved low-dose rifabutin-containing all-in-one combination treatment for H. pylori, is now available on prescription to treat adults with H. prnewswire.com - 2 months ago

Israel-Based RedHill's Investigational COVID-19 Treatment Shows Encouraging Action In Obesity And Diabetes On Monday, RedHill Biopharma Ltd. RDHL released results from multiple in vivo studies, undertaken by RedHill's partner, Apogee Biotechnology Corporation. benzinga.com - 2 months ago

8. Profile Summary

RedHill Biopharma Ltd. RDHL

COUNTRY IL

INDUSTRY Drug Manufacturers - Specialty & Generic

MARKET CAP $ 9.29 M

Dividend Yield 0.00%

Description RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.

Contact 21 Ha’arba’a Street, Tel Aviv, 6473921 https://www.redhillbio.com

IPO Date Jan. 7, 2013

Employees 53

Officers Mr. Gilead Raday MPhil, MSc Chief Operating Officer Mr. Rick D. Scruggs Chief Commercial Officer, President of RedHill Biopharma Inc. & Director Ms. Alexandra Okmian Senior Business Development & Investor Relations Manager Dr. Reza Fathi Ph.D. Senior Vice President of Research & Development Ms. Patricia Anderson B.Sc. RAC Senior Vice President of Regulatory Affairs Mr. Adi Frish Chief Corporate & Business Development Officer Mr. Razi Ingber Chief Financial Officer Mr. Dror Ben-Asher Co-Founder, Chairman & Chief Executive Officer Mr. Guy Goldberg J.D. Chief Business Officer

Price Chart RDHL

RedHill Biopharma Ltd. RDHL

Premium Plan

Unlimited Plan